PREDICTIVE ONCOLOGY INC (POAI) Stock Overview
USA - NASDAQ:POAI - US74039M3097 - Common Stock
POAI Key Statistics, Chart & Performance
The current stock price of POAI is 8.46 USD. In the past month the price decreased by -40%. In the past year, price decreased by -18.28%.
POAI Latest News, Press Relases and Analysis
POAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.98 | 216.98B | ||
| ISRG | INTUITIVE SURGICAL INC | 61.56 | 190.00B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.09 | 149.02B | ||
| SYK | STRYKER CORP | 28.02 | 141.06B | ||
| MDT | MEDTRONIC PLC | 16.45 | 116.69B | ||
| BDX | BECTON DICKINSON AND CO | 12.57 | 51.42B | ||
| IDXX | IDEXX LABORATORIES INC | 52.33 | 50.28B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.48 | 49.01B | ||
| RMD | RESMED INC | 25.48 | 36.81B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.34 | 34.24B | ||
| DXCM | DEXCOM INC | 36.67 | 26.75B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.43 | 26.26B |
Related stock screener links
About POAI
Company Profile
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2009-12-18. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The firm offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Company Info
PREDICTIVE ONCOLOGY INC
91 43Rd Street, Suite 110
Pittsburgh PENNSYLVANIA 55121 US
CEO: Carl Schwartz
Employees: 23
Phone: 14124321500
PREDICTIVE ONCOLOGY INC / POAI FAQ
What does PREDICTIVE ONCOLOGY INC do?
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2009-12-18. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The firm offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Can you provide the latest stock price for PREDICTIVE ONCOLOGY INC?
The current stock price of POAI is 8.46 USD. The price decreased by -4.3% in the last trading session.
Does POAI stock pay dividends?
POAI does not pay a dividend.
How is the ChartMill rating for PREDICTIVE ONCOLOGY INC?
POAI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is PREDICTIVE ONCOLOGY INC (POAI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on POAI.
What is the expected growth for POAI stock?
The Revenue of PREDICTIVE ONCOLOGY INC (POAI) is expected to grow by 569.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of POAI stock?
PREDICTIVE ONCOLOGY INC (POAI) has a market capitalization of 43.65M USD. This makes POAI a Nano Cap stock.
POAI Technical Analysis
POAI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to POAI. POAI has a bad profitability rating. Also its financial health evaluation is rather negative.
POAI Financial Highlights
Over the last trailing twelve months POAI reported a non-GAAP Earnings per Share(EPS) of -20.64. The EPS increased by 59.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -284.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
POAI Forecast & Estimates
For the next year, analysts expect an EPS growth of 99.58% and a revenue growth 569.48% for POAI